Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients With Nonactive Secondary Progressive Multiple Sclerosis

20260 citationsJournal Articlegold Open Access

Authors

Tanuja Chitnis · Brigham and Women's Hospital

Tarun Singhal · Brigham and Women's Hospital

Jonathan Zurawski · Brigham and Women's Hospital

Taylor J. Saraceno · Brigham and Women's Hospital

Niveditha Gopalakrishnan · Brigham and Women's Hospital

Lauren Cain · Brigham and Women's Hospital

Brenna A. LaBarre

Abstract

Progression independent of relapses (PIRA) is a major therapeutic challenge in multiple sclerosis (MS). Nasal anti-CD3 treats animal models of progressive MS by inducing regulatory T cells (Tregs) that suppress CNS inflammation and lessen clinical disease.

Topics & Keywords

Multiple Sclerosis Research Studies Advanced Drug Delivery Systems Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology Neuroimmunology & Neuroinflammation

Volume 13, Issue 2

DOI: 10.1212/nxi.0000000000200543

Field-Weighted Citation Impact: 0.00